Effect of Hedan Tablets combined with Atorvastatin on serum lipids and inflammatory factors in cerebral infarction with sleep apnea-hypopnea patients
ZHAO Huixin1 LI Xiaofang1 WANG Chuhan1 ZHANG Zeming2 ZHANG Xinghong1▲
1.Department of Neurology, the Affiliated Hospital of Hebei University, Hebei Province, Baoding 071000, China; 2.Department of Respiration, the Affiliated Hospital of Hebei University, Hebei Province, Baoding 071000, China
Abstract:[Abstract] Objective To investigate the effects of Hedan Tablets combined with Atorvastatin for serum lipids and inflammatory factors of cerebral infarction with sleep apnea-hypopnea patients. Methods Total 74 cases of cerebral infarction with sleep apnea-hypopnea patients admitted to the Affiliated Hospital of Hebei University from January 2013 to June 2015 were selected as research objects. The patients were randomly divided into control group (n = 37) and observation group (n = 37). The control group was treated with oral administration of Atorvastatin for 4 weeks, the observation group was treated with oral administration of Hedan Tablets combined with Atorvastatin for 4 weeks. Before and after treatment the serum triglyceride (TG), total cholesterol (TC), low density lipoprotein C (LDL-C), high-sensitivity C-reactive protein (hs-CRP) and soluble intercellular adhesion molecules-1 (sICAM-1) were determined. Results After treatment, the levels of serum TG [(2.549±0.441), (2.854±0.444) mmol/L], TC[(2.865±1.035), (2.992±0.991) mmol/L], LDL-C[(1.778±0.486), (1.827±0.527) mmol/L], hs-CRP[(1.846±0.607), (2.230±0.799) mg/L] and sICAM-1[(315.532±39.717), (345.108±30.733) ng/mL] in observation group and control group were all lower than those [(3.630±0.548), (3.862±0.683) mmol/L;(5.878±0.999), (5.757±1.062) mmol/L; (3.687±0.581), (3.538±0.658) mmol/L; (4.500±1.432), (4.422±1.540) mg/L; (397.762±33.752), (409.243±39.001) ng/mL] before treatment, the differences were all statistically significant (P < 0.01). After treatment, there were no statistically significant differences of the levels of serum TC and LDL-C between observation group and control group (P > 0.05). The levels of serum TG, hs-CRP and sICAM-1 in control group were lower than those of observation group after treatment, the differences were statistically significant (P < 0.05 or P < 0.01). Conclusion Hedan Tablets combined with atorvastatin has strong effects of lipid-lowering in cerebral infarction with sleep apnea-hypopnea patients. Hedan tablet combined with atorvastatincan strengthens the inflammatory response.